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Purpose: To evaluate the success rate and complications of single-plate Molteno tube 
implantation in patients with intractable glaucoma. 
Methods: We reviewed the records of patients who had undergone single-plate Molteno 
tube implantation from 1995 to 2000 with at least 18 months of follow up. 
Results: Thirty-six eyes of 35 (20 male and 15 female) patients with mean age of 29.7± 
25.3 (range 3-77) years were enrolled in the study. Preoperative intraocular pressure 
(IOP) was 34.5±10.4 mmHg with a mean of 2.3±0.8 medications which decreased   
to 18.0±7.6 mmHg with 1.9±1.2 medications after 32.8±16.1 months of follow up   
(P<0.0001). Complete success (IOP: 7-21 mmHg without medications), incomplete 
success (IOP: 7-21 mmHg with medication) and total success (sum of complete and 
incomplete success) rates were 19.5%, 55.6%, and 75%, respectively. At final follow up, 
visual acuity improved ≥1 line in 10 (27.8%), decreased ≥1 line in 8 (22.2%) and 
remained unchanged in 18 (50%) eyes. Postoperative complications occurred in 20 eyes 
(55.6%) including encapsulated bleb in 10 eyes (27.8%), tube-iris touch in 4 (11%), flat 
anterior chamber in 3 (8.4%), tube-cornea touch in 2 (5.6%), and retinal detachment, 
tube-lens touch, and tube blockage, each in 1 (2.8%). IOP dropped to zero in one eye 
resulting in visual loss. 
Conclusion: In eyes at high risk for trabeculectomy failure, implantation of the Molteno 
tube can be considered as a procedure with acceptable success for control of IOP and 
preservation of vision. Long term follow-up is recommended to ensure timely 
management of the frequent complications of this procedure. 
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INTRODUCTION 
 
Trabeculectomy is the most common surgical 
procedure used to increase aqueous drainage 
for glaucoma management. However it may 
not be technically feasible or have a low success 
rate in eyes with severe conjunctival scarring 
secondary to previous ocular surgery and 
many other high risk conditions such as neova-
scular, aphakic or uveitic glaucoma. Aqueous 
drainage devices are recommended in such 
cases.1,2 Shunt implantation is very effective in 
controlling IOP in cases with advanced or ref-
ractory glaucoma, but is associated with many  
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complications.3,4 Furthermore, the majority of 
patients require antiglaucoma medications for 
better IOP control after surgery.5 Herein we 
report our experience with single-plate Molteno 
implants at Farabi Eye Hospital, Tehran, Iran. 
 
METHODS 
 
This interventional case series includes all cases 
of single-plate Molteno tube implantation pro-
cedures performed in a single-stage fashion 
from 1995 to 2000. Overall, the medical records 
of 36 eyes of 35 patients with more than 18 mo-
nths of follow up were reviewed. Data included 
age at surgery, sex, diagnosis, number and type 
of previous surgical procedures, pre- and post-
operative IOP and number of antiglaucoma 
medications, visual acuity, follow up duration, 
and complications. 
Success and failure were defined as 
follows:  
• Complete success: IOP 7-21 mmHg without 
antiglaucoma medications.  
• Incomplete success: IOP 7-21 mmHg with 
antiglaucoma medications.  
• Total success: sum of complete and incom-
plete success.  
• Failure: IOP ≥22 mmHg despite use of medi-
cations, permanent hypotony (IOP≤6 mm-
Hg), phthisis bulbi, loss of light perception, or 
complications necessitating removal of the 
shunt. 
 
Surgical Technique 
 
One glaucoma specialist (HA) performed or 
supervised all operations using the same tech-
nique. Traction sutures with 7-0 Vicryl were 
placed 1.5 mm posterior to the limbus at 6 and 
12 clock hour positions followed by a fornix-
based conjunctival peritomy in the supero-
temporal quadrant. Tenon's capsule was 
completely separated from the sclera at the site 
of the peritomy. After ensuring that the shunt 
device is intact, the tube was occluded in front 
of the plate by means of a 6-0 Vicryl suture. The 
plate of the device was sutured to the sclera 10 
mm from the limbus with 7-0 silk or 8-0 nylon. 
A paracenthesis was then performed with a 23-
gauge needle at the limbus in the space bet-
ween the cornea and iris, parallel to the iris. 
The appropriately trimmed tube was inserted 
through the needle tract bevel side up. The 
extraocular portion of the tube was sutured to 
the sclera by one 10-0 nylon mattress suture. 
The tube was fenestrated in the extraocular 
portion with the needle of the 7-0 Vicryl suture 
to ensure aqueous drainage during the time for 
degradation of the Vicryl suture. A scleral 
patch graft 4×6 mm in size was used to cover 
the exposed portion of the tube. The con-
junctiva was then sutured using 10-0 nylon. 
Subconjunctival antibiotic and steroid was 
administered at the end of the operation and 
the eye was patched. A topical antibiotic was 
prescribed for 1 month and a topical steroid 
was prescribed for 2 months postoperatively. 
 
 
RESULTS 
 
This study includes 36 eyes of 35 patients 
including 20 male (57%) and 15 female (43%) 
subjects with mean age of 29.7±25.3 (range 3-77) 
years and mean follow up of 32±16.1 (range 18-
72) months. Mean preoperative IOP was 34.5± 
10.4 mmHg with 2.3±0.8 antiglaucoma medica-
tions which was reduced to 18±7.6 mmHg with 
1.9±1.2 antiglaucoma medications by the end of 
the follow up period (P<0.0001). 
The glaucoma diagnoses included congeni-
tal (14 eyes), aphakic/pseudophakic (11 eyes), 
traumatic (7 eyes), and primary open angle 
glaucoma (POAG, 4 eyes). Previous glaucoma 
surgical procedures were as follows: inferotem-
poral trabeculotomy and superonasal trabecul-
otomy-trabeculectomy at least once in the 
congenital glaucoma group, trabeculectomy at 
least once in the aphakic/pseudophakic and 
traumatic groups, and trabeculectomy at least 
twice in the POAG group. 
Overall and subgroup success rates are 
presented in tables 1 and 2. Complete, incom-
plete, and total success was achieved in 19.4%, 
55.6%, and 75% of eyes by the end of the follow 
up period, respectively.  
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Table 1 Success rates during follow up 
No. (%) 
Follow up 
Complete success  Incomplete success  Total success 
1 day  6 (16.7)  23 (63.9)  29 (80.6) 
6 months  5 (13.9)  21 (58.3)  26 (72.2) 
12 months  7 (19.4)  21 (58.3)  28 (77.8) 
18 months  7 (19.4)  21 (58.3)  28 (77.8) 
Final visit  7 (19.4)  20 (55.6)  27 (75.0) 
 
 
Table 2 Total success rate by glaucoma diagnosis at different follow up intervals 
Glaucoma diagnosis: No. (%) 
Follow up  Congenital 
(n=14) 
Aphakic/pseudophakic 
(n=11) 
Traumatic  
(n=7) 
POAG  
(n=4) 
1 day  12 (85.7)  9 (81.8)  4 (57.1)  4 (100) 
6 months  13 (92.9)  7 (63.6)  4 (57.1)  2 (50) 
12 months  10 (71.4)  10 (90.9)  5 (71.4)  3 (75) 
18 months  10 (71.4)  10 (90.9)  5 (71.4)  3 (75) 
POAG: primary open angle glaucoma 
 
 
Postoperative IOP gradually increased du-
ring time such that mean IOP was 13.4 mmHg 
without any medication on day 1 which increa-
sed to 18 mmHg with use of antiglaucoma me-
dications at final follow up (Fig.1). Postoperat-
ive complications were noted in 20 eyes (55.6%) 
(table 3). Encapsulated bleb, fibrotic tissue sur-
rounding the shunt plate, was the most fre-
quent complication.  
Visual acuity improved (≥1 Snellen line) 
in 10 eyes (27.8%) and deteriorated in 8 eyes 
(22.3%) by the end of the follow up period. 
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Figure 1 Mean intraocular pressure (IOP) before and at 
different follow up periods 
 
Table 3 Postoperative complications* 
Complication  N (%) 
Encapsulated bleb  10 (27.8) 
Tube-Iris touch  4 (11.2) 
Flat anterior chamber  3 (8.4) 
Tube-corneal touch  2 (5.6) 
Hypotony (IOP = 0 mmHg)  1 (2.8) 
Retinal detachment  1 (2.8) 
Tube-lens touch  1 (2.8) 
Tub obstruction by iris  1 (2.8) 
*Some eyes developed more than one complication.  
 
 
DISCUSSION 
 
Glaucoma drainage devices consist of two por-
tions: tube and plate. The tube is inserted into 
the anterior chamber and the plate is fixated on 
the sclera. Some shunt devices are valved such 
as the Ahmed and Krupin implants and some 
are not such as the Molteno and Baerveldt im-
plants. In valved devices, the valve mechanism 
opens at IOP of 10-12 mmHg and closes at IOP 
of 8 mmHg. This function decreases the pro-
bability of early postoperative hypotony.2,6,7 In 
non-valved devices, 2 methods are employed   
to prevent early postoperative hypotony. One  
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method is the staged procedure in which the 
tube is inserted 6 weeks after fixation of the 
plate. The other method is to occlude the tube 
at the time of implantation with a 7-0 or 6-0 
Vicryl suture to prevent the outflow of aqueous 
fluid for 4-5 weeks during which the suture 
will be degraded and a fibrotic capsule will be 
formed surrounding the tube preventing exce-
ssive aqueous outflow. 
Although success rates of 90-100% have 
been reported following glaucoma shunt pro-
cedures,8-10 the results of our study were similar 
to those of most previous studies.11-15 Variati-
ons in implant types, surgical technique, length 
of follow up, success criteria and underlying 
disorders in different studies limit comparison. 
However, 60-80% of eyes with Molteno tube 
implants had IOP of 22-24 mmHg for at least 
one year postoperatively.2  
In the current study, IOP was within the 
range of 7-21 mmHg with or without medica-
tion in 75%of eyes with an average follow up of 
32.8 months. Millis et al14 reported the results  
of Molteno tube implantation in 77 eyes and 
reported a total success rate of 57% with mean 
follow up of 44 months. Broadway et al15 stated 
total success rate of 60.5% for Molteno tube im-
plants in 119 eyes after 43 months. Total success 
rates in various diagnostic subgroups were 83% 
for aphakic/pseudophakic, 80% for uveitic, 
73% for POAG, and 50% for developmental 
glaucoma. Although success rate was higher in 
eyes with aphakic/pseudophakic glaucoma, 
the authors mentioned this condition as a risk 
factor for failure. Freedman and Rubin11 re-
ported incomplete success rate of 72% after 
mean follow up of 30 months in a group of 82 
black patients with refractory glaucoma.  
Eid et al16 reported the results of tube-
shunt procedures on 18 eyes of 15 patients after 
a mean follow up of 43.3 months and found 
that 5 cases (27.8%) lost light perception and 7 
cases (38.8%) maintained visual acuity within 1 
Snellen line compared to preoperative values. 
In our series, postoperative visual acuity 
improved in 27.8%, decreased in 22.3% and 
remained unchanged in 50%. 
Overall, complications encountered in our 
study were similar to other reports,5,15 however 
certain complications such as choroidal hemo-
rrhage, corneal edema, chronic intraocular in-
flammation, hyphema, and cataract which have 
been reported in other studies,4,7,15 were not 
observed in our series.  
Complications of tube shunt surgery are 
relatively common11-15 and there is evidence 
that adjunctive use of mitomycin C may in-
crease the rate of certain complications such as 
early postoperative hypotony,17 tube erosion 
through the conjunctiva,18 and tube blockage.19 
Therefore, antiproliterative agents should be 
considered in eyes thought to be at high risk of 
tube failure such as traumatic glaucoma, neo-
vascular glaucoma, younger age, and multiple 
previous surgeries with extensive conjunctival 
scar.15,17 Ocular hypotony is one of the reported 
complications in shunt surgery.16  We did not 
use any antimetabolite agent in our series. In 
one of our cases, IOP reached zero and further 
intervention was not performed because of 
poor vision.  
In conclusion, the results of our study 
show that single stage implantation of a single-
plate Molteno device is effective and relatively 
safe for management of intractable glaucoma in 
eyes at high risk for trabeculectomy failure. 
Considering the high rate of post-operative 
complications, regular and long term follow up 
seems to be essential for timely detection and 
management. 
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